Stockscreener 앱 받기
9.21
2.33%
0.21
시장 영업 전:
9.20
-0.01
-0.11%
전일 마감가:
$9.00
열려 있는:
$9.1
하루 거래량:
749.45K
Relative Volume:
0.90
시가총액:
$557.48M
수익:
-
순이익/손실:
$-161.31M
주가수익비율:
-2.5196
EPS:
-3.6553
순현금흐름:
$-154.85M
1주 성능:
+5.86%
1개월 성능:
+3.83%
6개월 성능:
+32.52%
1년 성능:
+332.39%
1일 변동 폭
$8.95
$9.38
1주일 범위
$8.25
$9.38
52주 변동 폭
$1.92
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
Compare KYTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
9.21 | 557.48M | 0 | -161.31M | -154.85M | -3.6553 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-05-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday - MarketBeat
Kyverna appoints Nadia Dac as chief commercial officer By Investing.com - Investing.com Australia
Kyverna appoints Nadia Dac as chief commercial officer - Investing.com UK
Kyverna Therapeutics Appoints Nadia Dac as Chief Commercial Officer to Lead Launch of miv-cel for Stiff Person Syndrome and Neuroimmunology Expansion - Minichart
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth - TipRanks
Kyverna brings in a 30-year launch veteran for its commercial push - Stock Titan
Kyverna (NASDAQ: KYTX) hires Nadia Dac as CCO with 300,000-share option - Stock Titan
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer - Yahoo Finance
AIGH Capital Management LLC Acquires Shares of 1,500,000 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
KYTX stock soars after hours: What’s driving the rally? - MSN
KYTX Stock Price, Quote & Chart | KYVERNA THERAPEUTICS INC (NASDAQ:KYTX) - ChartMill
JP Morgan initiated coverage on Kyverna Therapeutics with a new price target - Quantisnow
Kyverna rises on new mid-stage trial data for myasthenia gravis therapy - MSN
Kyverna Therapeutics (KYTX) stock surges 24% after hours: Why is it moving? - MSN
KYTX Price Today: Kyverna Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA - MarketBeat
Peapod Lane Capital LLC Decreases Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Kyverna Therapeutics' (KYTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Kyverna Therapeutics stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Kyverna Therapeutics stock rating at buy - Investing.com
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet - Seeking Alpha
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis - Seeking Alpha
Walking the talk, Kyverna phase II stiffens miv-cel CAR T case - BioWorld News
Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap UpShould You Buy? - MarketBeat
Kyverna’s Miv-cel Achieves Breakthrough Results in Stiff Person Syndrome, Paving Way for First Approved Therapy - Minichart
Kyverna Therapeutics Unveils Transformative CAR T Therapy Data for Stiff Person Syndrome and Generalized Myasthenia Gravis at AAN 2026 - Minichart
KYTX: miv-cel delivers unprecedented, durable efficacy and safety in SPS and GMG, supporting strong launch potential - TradingView
Kyverna announces strong Phase 2/3 CAR T neuroimmunology data - TipRanks
KYTX: Miv-cel achieved durable, drug-free remission and robust clinical benefit in SPS and gMG - TradingView
Miv-cel data position Kyverna (NASDAQ: KYTX) for SPS BLA and gMG Phase 3 - Stock Titan
Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome - TipRanks
KYTX: Miv-cel showed robust, durable efficacy and safety in SPS, with all patients off chronic immunotherapies - TradingView
Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving? - Benzinga
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
Kyverna Therapeutics announces positive primary analysis results from KYSA-8 trial of Miv-Cel in SPS - marketscreener.com
Kyverna Therapeutics Announces Positive Primary Analysis Results From KYSA-8 Trial Of Miv-Cel In SPS - TradingView
Kyverna Therapeutics Reports Positive Trial Results for Miv-cel in Stiff Person Syndrome, Highlighting Potential to Transform Treatment Paradigm - Quiver Quantitative
Miv-cel delivers significant SPS gains in Kyverna (NASDAQ: KYTX) registrational trial - Stock Titan
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting - Yahoo Finance
KEI Comments on Exclusive License to Kyverna Therapeutics - Knowledge Ecology International
Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 7.2%Should You Sell? - MarketBeat
Kyverna Therapeutics Inc (KYTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):